Table 1

Anthropometric and clinical characteristics of study participants

MaleFemale
MolOBB Affymetrix study participants
 n3118
 Age, years48 (40–56)50 (39–56)
 BMI, kg/m228.2 (21.4–40.5)30.2 (22.6–45.5)
 Waist, cm98.2 (79.0–134.0)95.4 (75.0–131.0)
 Hip, cm106.0 (94.0–126.0)110.0 (93.0–141.0)
 WHR0.92 (0.82–1.08)0.86 (0.77–1.05)
 Fasting glucose, mmol/L5.4 (4.7–7.1)5.4 (4.6–8.6)
 Fasting insulin, mU/L13.8 (5.8–53.3)12.3 (4.4–31.8)
Arteriovenous study participants
 n2319
 Age, years41 (22–59)41 (23–57)
 BMI, kg/m225.4 (20.8–30.6)25.4 (21.0–39.3)
 WHR0.92 (0.79–1.05)0.84 (0.72–0.97)
 Abdominal fat mass, kg10.6 (4.5–17.0)12.6 (4.0–25.5)
 Leg fat mass, kg5.8 (3.5–8.7)8.6 (4.7–15.3)
 Fasting glucose, mmol/L5.4 (4.8–6.6)5.0 (4.4–5.6)
 Fasting insulin, mU/L11.6 (7.2–20.8)11.7 (3.8–27.3)
 Fasting nonesterified fatty acids, µmol/L513 (300–1,084)659 (297–1,012)
 Serum IL-6, pg/mL1.6 (0.26–9.14)0.96 (0.31–2.69)
 Serum MCP-1, pg/mL7.67 (4.79–14.76)6.86 (2.81–10.93)
 Serum leptin, pg/mL991 (69–5,375)3,481 (333–18,000)
 Abdominal ATBF3.4 (0.3)3.5 (0.4)
 Gluteofemoral ATBF2.5 (0.3)3.4 (0.4)
  • All data other than ATBF are presented as mean (minimum–maximum). ATBF data are presented as mean (± SEM) in mL · min–1 · 0.100 g tissue–1.